A61K 47/6877
The antibody being an immunoglobulin containing regions, domains or residues from different
Official title: {the antibody being an immunoglobulin containing regions, domains or residues from different species}
A61K47/6877 (The antibody being an immunoglobulin containing regions, domains or residues from different) appears on 89 US grants and 116 published applications in this corpus.
Search patents in A61K- Granted patents
- 89
- Published applications
- 116
- Assignees
- 83
- Inventors
- 339
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 3 |
| 2003 | 3 | 2 |
| 2004 | 3 | 1 |
| 2005 | 1 | 2 |
| 2006 | 1 | 2 |
| 2007 | 0 | 2 |
| 2008 | 1 | 2 |
| 2009 | 1 | 3 |
| 2010 | 3 | 0 |
| 2011 | 0 | 3 |
| 2012 | 3 | 3 |
| 2013 | 0 | 1 |
| 2014 | 1 | 5 |
| 2015 | 3 | 4 |
| 2016 | 3 | 3 |
| 2017 | 8 | 8 |
| 2018 | 1 | 5 |
| 2019 | 2 | 3 |
| 2020 | 3 | 3 |
| 2021 | 0 | 6 |
| 2022 | 3 | 6 |
| 2023 | 6 | 10 |
| 2024 | 7 | 11 |
| 2025 | 5 | 20 |
| 2026 | 9 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Meditopes and meditope-binding antibodies and uses thereof25 Aug 2026US 12,714,753 B2City of Hope
- Combination of antibody-pyrrolobenzodiazepine derivative conjugate and PARP inhibitor9 Jun 2026US 12,648,946 B2Daiichi Sankyo Company, Limited
- Humanized anti-GPC-1 antibody2 Jun 2026US 12,643,955 B2Iwate Medical University
- Antibody against Nectin-4 and application thereof31 Mar 2026US 12,590,150 B2Mabwell (Shanghai) Bioscience Co., Ltd.
- Eribulin antibody-drug conjugates and methods of use3 Mar 2026US 12,564,641 B2Eisai R&D Management Co., Ltd.
- Eribulin antibody-drug conjugates and methods of use20 Aug 2026US 2026/0241017 A1Eisai R&D Management Co., Ltd.
- Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof20 Aug 2026US 2026/0242515 A1Duality Biologics (Shanghai) Co., Ltd.
- Antibodies specific to transmembrane and coiled-coil domain family 3 and uses thereof30 Jul 2026US 2026/0217854 A1Chang Gung Memorial Hospital, Linkou
- Antibody-drug conjugate, and preparation method therefor and use thereof18 Jun 2026US 2026/0166168 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Compositions and methods for treating cancers18 Jun 2026US 2026/0167745 A1
Most cited
By later US patents
- Chimeric antibody with specificity to human B cell surface antigen853US 5,500,362 AXoma Corporation · 1996
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells304US 5,789,554 AImmunomedics, Inc. · 1998
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells237US 6,187,287 B1Immunomedics, Inc. · 2001
- Chimeric antibody with specificity to human B cell surface antigen138US 5,677,180 AXoma Corporation · 1997
- Chimeric antibody with specificity to human B cell surface antigen120US 5,721,108 AXoma Corporation · 1998